AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.300
+0.240 (22.64%)
Nov 20, 2024, 4:00 PM EST - Market closed
AN2 Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Net Income | -60.7 | -64.73 | -40.96 | -21.54 | -13.6 | -33.81 |
| Asset Writedown & Restructuring Costs | - | - | - | - | 0.65 | 16.21 |
| Loss (Gain) From Sale of Investments | -4.02 | -2.86 | -0.69 | 0.05 | - | - |
| Stock-Based Compensation | 8.79 | 8.41 | 4.39 | 0.97 | 0.04 | - |
| Other Operating Activities | - | 0.05 | 0.08 | - | 6.32 | 2.74 |
| Change in Accounts Payable | -3.07 | 0.55 | 2.5 | 0.42 | 0.08 | -0.1 |
| Change in Other Net Operating Assets | -2.06 | 5.28 | 1.22 | -0.39 | 1.14 | 0.04 |
| Operating Cash Flow | -61.05 | -53.29 | -33.46 | -20.48 | -5.36 | -14.92 |
| Investment in Securities | 61.89 | -43.28 | -21.77 | -50.02 | - | - |
| Investing Cash Flow | 61.89 | -43.28 | -21.77 | -50.02 | - | - |
| Issuance of Common Stock | 0.05 | 84.99 | 70.37 | 0.01 | 0.06 | - |
| Repurchase of Common Stock | - | - | -0.01 | - | - | - |
| Other Financing Activities | - | - | - | -1.21 | - | - |
| Financing Cash Flow | 0.05 | 84.99 | 70.36 | 78.54 | 3.84 | 48.5 |
| Net Cash Flow | 0.89 | -11.57 | 15.12 | 8.03 | -1.53 | 33.59 |
| Free Cash Flow | -61.05 | -53.29 | -33.46 | -20.48 | -5.36 | -14.92 |
| Free Cash Flow Per Share | -2.05 | -2.26 | -2.18 | -7.76 | -2.09 | -5.84 |
| Levered Free Cash Flow | -38.56 | -28.85 | -19.3 | -11.96 | -3.27 | - |
| Unlevered Free Cash Flow | -38.56 | -28.85 | -19.3 | -11.96 | -3.27 | - |
| Change in Net Working Capital | 6.49 | -6.26 | -2.73 | -0.55 | -1.24 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.